The DOI matches its Crossref record; 405 of the 406 references it cites were found in a registry or an index.
Reduced Vancomycin Susceptibility in Staphylococcus aureus , Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications
Open accessAbstract
SUMMARY: The emergence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) over the past decade has provided a challenge to diagnostic microbiologists to detect these strains, clinicians treating patients with infections due to these strains, and researchers attempting to understand the resistance mechanisms. Recent data show that these strains have been detected globally and in many cases are associated with glycopeptide treatment failure; however, more rigorous clinical studies are required to clearly define the contribution of hVISA to glycopeptide treatment outcomes. It is now becoming clear that sequential point mutations in key global regulatory genes contribute to the hVISA and VISA phenotypes, which are associated predominately with cell wall thickening and restricted vancomycin access to its site of activity in the division septum; however, the phenotypic features of these strains can vary because the mutations leading to resistance can vary. Interestingly, changes in the staphylococcal surface and expression of agr are likely to impact host-pathogen interactions in hVISA and VISA infections. Given the subtleties of vancomycin susceptibility testing against S. aureus , it is imperative that diagnostic laboratories use well-standardized methods and have a framework for detecting reduced vancomycin susceptibility in S. aureus .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Due to the difficulties on detecting these strains, vancomycin failures have been increasingly reported in deep-seated infections.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“Indeed, S. aureus within the range of susceptibility, with vancomycin MICs > 1 and ≤ 2 μg/ml have been more frequently associated with the hVISA phenotype.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“These global homeostatic changes appear to lead to a reduced autolytic activity with thickened cell wall and an increase amount of free D-Ala-D-Ala dipeptides with less peptidoglycan cross-linking (101, 104).”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“Phenotypically, hVISA/VISA strains exhibit distinct metabolic characteristics that may include i) increase in fructose utilization, ii) increased fatty acid metabolism, iii) impaired acetate metabolism and tricarboxylic acid cycle, iv) decrease in glutamate availability, and iv) increase expression of cell wall synthesis genes.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“As the “resistant” subpopulation is difficult to identify, detection of hVISA becomes very challenging and some S. aureus strains reported as “susceptible” to vancomycin by standard susceptibility testing may still exhibit this phenotype (101).”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“In addition, VISA strains bind vancomycin more avidly than their non –VISA counterparts, however, diffusion of the antibiotic molecule into the inner part of the cell wall appears to be impaired.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
In the citing paper
“Finally, a striking feature of many hVISA/VISA strains is the ability to revert from one phenotype to another (or even to a fully vancomycin susceptible phenotype) in the absence of vancomycin exposure.”
From Mechanisms of Antibiotic Resistance (2016) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,018
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726
Lew, D. P., & Waldvogel, F. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16727-5 · Cited by 1,988
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Vandenesch, F., Naimi, T. S., Enright, M. C., Lina, G., Nimmo, G. R., Heffernan, H., Liassine, N., Bes, M., Greenland, T., Reverdy, M. E., et al. (2003) · Emerging infectious diseases · doi:10.3201/eid0908.030089 · Cited by 1,718
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
The Changing Epidemiology of Staphylococcus aureus ?
Chambers, H. F. “. (2001) · Emerging infectious diseases · doi:10.3201/eid0702.010204 · Cited by 1,419
Plasmid-Mediated Resistance to Vancomycin and Teicoplanin in Enterococcus Faecium
Leclercq, R., Derlot, E., Duval, J., & Courvalin, P. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807213190307 · Cited by 1,411
Diekema, D. J., Pfaller, M. A., Schmitz, F., Smayevsky, J., Bell, J. M., Jones, R. N., Beach, M. L., & SENTRY Participants Group (2001) · Clinical Infectious Diseases · doi:10.1086/320184 · Cited by 1,363
Research works printed but not linked: 1
- Ferraz, V., A. G. Duse, M. Kassel, A. D. Black, T. Ito, and K. Hiramatsu. 2000. Vancomycin-resistant Staphylococcus aureus occurs in South Africa. S. Afr. Med. J.90:1113.
Cited by
Sorted by citations
Items 201–300 of 962
Leonard, S. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042103 · Cited by 49
Zhou, Z., Ma, C., Zhang, H., Bi, Y., Chen, X., Tian, H., Xie, X., Meng, Q., Lewis, P. J., & Xu, J. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.07.041 · Cited by 49
Sangboonruang, S., Semakul, N., Obeid, M. A., Ruano, M., Kitidee, K., Anukool, U., Pringproa, K., Chantawannakul, P., Ferro, V. A., Tragoolpua, Y., et al. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s325901 · Cited by 49
Roch, M., Clair, P., Renzoni, A., Reverdy, M. E., Dauwalder, O., Bes, M., Martra, A., Freydière, A.-M., Laurent, F. J., Reix, P., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02574-14 · Cited by 48
García, A., Viñuela-Prieto, J. M., González, L. L., & Candel, F. J. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s146748 · Cited by 48
Metabolic Mitigation of Staphylococcus aureus Vancomycin Intermediate-Level Susceptibility
Gardner, S. G., Marshall, D. D., Daum, R. S., Powers, R., & Somerville, G. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01608-17 · Cited by 46
Jiang, G., Liu, S., Yu, T., Wu, R., Ren, Y., van der Mei, H. C., Liu, J., & Busscher, H. J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.01.032 · Cited by 48
Singh, A. K., Ahmed, A., Prasad, K. N., Khanduja, S., Singh, S. K., Srivastava, J. K., & Gajbhiye, N. S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01440-15 · Cited by 47
Global proteome analysis of vancomycin stress in Staphylococcus aureus
Heßling, B., Bonn, F., Otto, A., Herbst, F., Rappen, G.-M., Bernhardt, J., Hecker, M., & Becher, D. (2013) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2013.08.014 · Cited by 47
Chang, W., Ma, X., Gao, P., Lv, X., Lu, H., & Chen, F. (2015) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.148837 · Cited by 47
Nh125 Kills Methicillin-Resistant Staphylococcus Aureus Persisters by Lipid Bilayer Disruption
Kim, W., Fricke, N., Conery, A. L., Fuchs, B. B., Rajamuthiah, R., Jayamani, E., Vlahovska, P. M., Ausubel, F. M., & Mylonakis, E. E. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc.15.189 · Cited by 47
Leuthner, K. D., Buechler, K., Kogan, D., Saguros, A., & Lee, S. P. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s86330 · Cited by 47
Foster, T. J., & Geoghegan, J. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397169-2.00037-8 · Cited by 57
Werth, B. J., Ashford, N. K., Penewit, K. M., Waalkes, A., Holmes, E. A., Ross, D. H., Shen, T., Hines, K. M., Salipante, S. J., & Xu, L. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.08.025 · Cited by 47
Epidemiology of Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infection
Gasch, O., Ayats, J., Domínguez, M. Á., Tubau, F., Liñares, J., Peña, C., Grau, I., Pallarés, R., Gudiol, F., Ariza, J., et al. (2011) · Medicine · doi:10.1097/md.0b013e31822f0b54 · Cited by 46
Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada
Nichol, K. A., Adam, H. J., Roscoe, D. L., Golding, G. R., Lagace-Wiens, P. R. S., Hoban, D. J., Zhanel, G. G., on behalf of the Canadian Antimicrobial Resistance Alliance (CARA), Zhanel, G. G., Hoban, D. J., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt026 · Cited by 48
Hines, K. M., Shen, T., Ashford, N. K., Waalkes, A., Penewit, K. M., Holmes, E. A., McLean, K., Salipante, S. J., Werth, B. J., & Xu, L. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz562 · Cited by 46
Whatʼs new in the treatment of serious MRSA infection?
Holmes, N. E., & Howden, B. P. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000101 · Cited by 45
Self-citationTransportan 10 improves the pharmacokinetics and pharmacodynamics of vancomycin
Ruczyński, J., Rusiecka, I., Turecka, K., Kozłowska, A., Alenowicz, M., Gągało, I., Kawiak, A., Rekowski, P., Waleron, K., & Kocić, I. (2019) · Scientific Reports · doi:10.1038/s41598-019-40103-w · Cited by 45
Environment Shapes the Accessible Daptomycin Resistance Mechanisms in Enterococcus faecium
Prater, A. G., Mehta, H. H., Kosgei, A. J., Miller, W. R., Tran, T. T., Arias, C. A., & Shamoo, Y. E. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00790-19 · Cited by 42
Pharmacokinetics and pharmacodynamics of peptide antibiotics
Bian, X., Qu, X., Zhang, J., Nang, S. C., Bergen, P. J., Zhou, Q. T., Chan, H., Feng, M., & Li, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114171 · Cited by 45
Vidaillac, C., Gardete, S., Tewhey, R., Sakoulas, G., Kaatz, G. W., Rose, W. E., Tomasz, A., & Rybak, M. J. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit127 · Cited by 45
Mediati, D. G., Wong, J. L., Gao, W., McKellar, S. W., Pang, C. N. I., Wu, S., Wu, W., Sy, B. M., Monk, I. R., Biazik, J. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31177-8 · Cited by 44
Self-citationStaphylococcus aureus with reduced susceptibility to vancomycin in healthcare settings
Spagnolo, A. M., Orlando, P., Panatto, D., Amicizia, D., Perdelli, F., & Cristina, M. L. (2015) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2014.55.4.454 · Cited by 44
Total Synthesis and Absolute Configuration Assignment of MRSA Active Garcinol and Isogarcinol
Socolsky, C., & Plietker, B. J. (2014) · Chemistry - A European Journal · doi:10.1002/chem.201406077 · Cited by 43
Montevecchi, M., Dorigo, A., Cricca, M., & Checchi, L. (2013) · PubMed · Cited by 44
Machado, H., Seif, Y., Sakoulas, G., Olson, C. A., Hefner, Y., Anand, A., Jones, Y., Szubin, R., Palsson, B. Ø., Nizet, V., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02339-z · Cited by 41
The war against bacteria, from the past to present and beyond
Bottalico, L., Charitos, I. A., Potenza, M. A., Montagnani, M., & Santacroce, L. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2013809 · Cited by 48
Bouchelaghem, S., Das, S., Naorem, R. S., Czuni, L., Papp, G., & Kocsis, M. (2022) · Molecules · doi:10.3390/molecules27020574 · Cited by 44
Antimicrobial resistance in Libya: 1970–2011
Ghenghesh, K. S., Rahouma, A., Tawil, K., Zorgani, A., & Franka, E. (2013) · Libyan Journal of Medicine · doi:10.3402/ljm.v8i0.20567 · Cited by 43
Osipovitch, D. C., & Griswold, K. E. (2014) · FEMS Microbiology Letters · doi:10.1093/femsle/fnu035 · Cited by 43
Claeys, K. C., Lagnf, A. M., Hallesy, J. A., Compton, M., Gravelin, A. L., Davis, S. L., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02388-15 · Cited by 43
Kamurai, B., Mombeshora, M., Mukanganyama, S., & Khamesipour, F. (2020) · International Journal of Microbiology · doi:10.1155/2020/8885338 · Cited by 43
Khairnar, S. V., Das, A., Oupický, D., Sadykov, M. R., & Romanova, S. (2025) · RSC Pharmaceutics · doi:10.1039/d4pm00314d · Cited by 47
Pitz, A. M., Yu, F., Hermsen, E. D., Rupp, M. E., Fey, P. D., & Olsen, K. M. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00914-10 · Cited by 42
Sheppard, J. G., McAleer, J. P., Saralkar, P. A., Geldenhuys, W. J., & Long, T. E. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.018 · Cited by 43
Galbusera, E., Renzoni, A., Andrey, D. O., Monod, A., Barras, C., Tortora, P., Polissi, A., & Kelley, W. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00720-10 · Cited by 41
Mirzaei, R., Ghaleh, H. E. G., & Ranjbar, R. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1030401 · Cited by 41
Huang, J., Lauderdale, T.-L. Y., & Shia, K. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b02039 · Cited by 41
Mashaly, G. E.-S., & El-Mahdy, R. H. (2017) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-017-0238-5 · Cited by 41
Mallela, A. N., Abdullah, K. G., Brandon, C., Richardson, A. G., & Lucas, T. H. (2017) · Neurosurgery · doi:10.1093/neuros/nyx559 · Cited by 41
Phillips‐Jones, M. K., & Harding, S. E. (2018) · Biophysical Reviews · doi:10.1007/s12551-018-0404-9 · Cited by 42
Richter, S. S., Diekema, D. J., Heilmann, K. P., Dohrn, C. L., Crispell, E. K., Riahi, F., McDanel, J. S., Satola, S. W., & Doern, G. V. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01915-13 · Cited by 40
Yoo, J. I., Kim, J. W., Kang, G. S., Kim, H. S., Yoo, J. S., & Lee, Y. S. (2013) · The Journal of Microbiology · doi:10.1007/s12275-013-3088-7 · Cited by 40
Hu, J., Xue, X., Tian, Y., Pang, L., Cui, L. Z., & Shang, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073300 · Cited by 40
An, M., Shen, H., Zhang, J. D., Xu, G. T., & Jiang, Y. Y. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.12.012 · Cited by 39
Richards, R. L., Haigh, R., Pascoe, B., Sheppard, S. K., Price, F. W., Jenkins, D. R., Rajakumar, K., & Morrissey, J. A. (2015) · Infection and Immunity · doi:10.1128/iai.00255-15 · Cited by 39
New Found Hope for Antibiotic Discovery: Lipid II Inhibitors
Ng, V., & Chan, W. C. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201601315 · Cited by 40
Comprehensive antibiotic-linked mutation assessment by resistance mutation sequencing (RM-seq)
Guérillot, R., Li, L. Q., Baines, S. L., Howden, B. P., Schultz, M. B., Seemann, T., Monk, I. R., Pidot, S. J., Gao, W., Giulieri, S. G., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0572-z · Cited by 39
Self-citationChen, F.-J., Lauderdale, T.-L. Y., Lee, C., Hsu, Y.-C., Huang, I., Hsu, P., & Yang, C. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01086 · Cited by 40
Using genomics to understand meticillin- and vancomycin-resistant Staphylococcus aureus infections
Giulieri, S. G., Tong, S. Y. C., & Williamson, D. A. (2020) · Microbial Genomics · doi:10.1099/mgen.0.000324 · Cited by 41
Garzoni, C., & Vergidis, P. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12098 · Cited by 40
Phage Therapy as an Alternative Treatment Modality for Resistant Staphylococcus aureus Infections
Atshan, S. S., Hamat, R. A., Aljaberi, M. A. A., Chen, J., Huang, S.-W., Lin, C., Mullins, B. J., & Kicic, A. (2023) · Antibiotics · doi:10.3390/antibiotics12020286 · Cited by 40
Song, Y., Lunde, C. S., Benton, B. M., & Wilkinson, B. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05403-11 · Cited by 38
Miller, C. E., Batra, R., Cooper, B. S., Patel, A., Klein, J. L., Otter, J. A., Kypraios, T., French, G. L., Tosas, O., & Edgeworth, J. D. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir858 · Cited by 39
Marcos, L. A., & Camins, B. C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00857-10 · Cited by 39
Campanile, F., Borbone, S., Perez, M., Bongiorno, D., Cafiso, V., Bertuccio, T., Purrello, S., Nicolosi, D., Scuderi, C., & Stefani, S. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.044 · Cited by 39
Wit, G. D., Svet, L., Lories, B., & Steenackers, H. P. L. (2022) · Annual Review of Microbiology · doi:10.1146/annurev-micro-041320-031627 · Cited by 39
Shu, X., Shi, Y., Huang, Y., Yu, D., & Sun, B. (2023) · Nature Communications · doi:10.1038/s41467-023-37949-0 · Cited by 38
Berscheid, A., François, P., Strittmatter, A. W., Gottschalk, G., Schrenzel, J., Saß, P., & Bierbaum, G. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku297 · Cited by 38
Pinchman, J. R., & Boger, D. L. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4004494 · Cited by 38
Genetic and Molecular Predictors of High Vancomycin MIC in Staphylococcus aureus Bacteremia Isolates
Holmes, N. E., Turnidge, J. D., Munckhof, W., Robinson, J. O., Korman, T. M., O'Sullivan, M. V. N., Anderson, T. L., Roberts, S., Warren, S. J. C., Coombs, G. W., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01320-14 · Cited by 38
Self-citationYang, C.-C., Sy, C.-L., Huang, Y., Shie, S., Shu, J., Hsieh, P., Hsiao, C., & Chen, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-26277-9 · Cited by 37
Santos, G. A. C., Dropa, M., Martone-Rocha, S., Peternella, F. A. S., & Razzolini, M. T. P. (2020) · Journal of Water and Health · doi:10.2166/wh.2020.042 · Cited by 38
Selim, S., Faried, O. A., Almuhayawi, M. S., Saleh, F. M., Sharaf, M., Nahhas, N. E., & Warrad, M. (2022) · Antibiotics · doi:10.3390/antibiotics11030408 · Cited by 40
Blazanovic, K., Zhao, H., Choi, Y., Li, W., Salvat, R. S., Osipovitch, D. C., Fields, J. L., Moise, L., Berwin, B. L., Fiering, S., et al. (2015) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.21 · Cited by 37
Rodríguez, C. A., Agudelo, M., Zuluaga, A. F., & Vesga, Ó. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05129-11 · Cited by 37
Peixoto, P. B., Massinhani, F. H., dos Santos, K. R. N., Chamon, R. C., Silva, R. B., Corrêa, F. E. L., de Oliveira, C. D. C. H. B., & de Oliveira, A. G. (2019) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001117 · Cited by 37
Bakthavatchalam, Y. D., Babu, P., Munusamy, E., Dwarakanathan, H. T., Rupali, P., Zervos, M., Victor, P. J., & Veeraraghavan, B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0227009 · Cited by 37
Soriano, À., Rossolini, G. M., & Pea, F. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1746643 · Cited by 37
Hernández-Aristizábal, I., & Ocampo-Ibáñez, I. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157927 · Cited by 38
Cázares‐Domínguez, V., Cruz‐Córdova, A., Ochoa, S. A., Escalona, G., Arellano‐Galindo, J., Rodríguez-Leviz, A., Hernández‐Castro, R., López‐Villegas, E. O., & Xicohtencatl‐Cortés, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118791 · Cited by 37
van Hal, S. J., & Paterson, D. L. (2011) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32834ab1de · Cited by 36
Liu, Y., Meng, X., Ma, Z., Gu, H., Luo, X., Yin, X., Yi, H., & Chen, Y. (2024) · Food Chemistry · doi:10.1016/j.foodchem.2024.141496 · Cited by 36
Gaur, R., Gupta, V., Pal, A., Darokar, M. P., Bhakuni, R. S., & Kumar, B. N. (2014) · RSC Advances · doi:10.1039/c4ra10842f · Cited by 36
Mirzaee, M., Peerayeh, S. N., Behmanesh, M., & Moghadam, M. F. (2015) · Current Microbiology · doi:10.1007/s00284-014-0771-9 · Cited by 36
Wu, Z., Isley, N. A., & Boger, D. L. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00152 · Cited by 36
Wang, L., Li, B., Si, X., Liu, X., Deng, X., Niu, X., Jin, Y., Wang, D., & Wang, J. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14371 · Cited by 36
Goldmann, O., Cern, A., Müsken, M., Rohde, M., Weiss, W., Barenholz, Y., & Medina, E. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.007 · Cited by 36
Kaur, H., Kalia, M., & Taneja, N. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104608 · Cited by 36
Zhang, X., Hu, Q., Yuan, W., Shang, W., Cheng, H., Yuan, J., Zhu, J., Hu, Z., Li, S., Chen, W., et al. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.06.008 · Cited by 36
Entenza, J. M., Bétrisey, B., Manuel, O., Giddey, M., Sakwińska, O., Laurent, F. J., & Bizzini, A. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01820-13 · Cited by 36
Infections of Diabetic Foot Ulcers With Methicillin-Resistant Staphylococcus aureus
Cervantes-García, E., García-González, R., Reséndiz‐Albor, A. A., & Salazar-Schettino, P. M. (2015) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734614564053 · Cited by 38
Yamakawa, J., Kurosawa, H., Kaneko, K., Yamakawa, J., AMINAKA, M., Hori, S., Cui, L., Ito, T., Jin, J., Hiramatsu, K., et al. (2011) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-011-0330-2 · Cited by 35
Genome Sequence-Based Discriminator for Vancomycin-Intermediate Staphylococcus aureus
Rishishwar, L., Petit, R. A., Kraft, C. S., & Jordan, I. K. (2013) · Journal of Bacteriology · doi:10.1128/jb.01410-13 · Cited by 35
Pajares‐Chamorro, N., Shook, J. C., Hammer, N. D., & Chatzistavrou, X. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.07.012 · Cited by 35
Wang, H., Chen, C., Chu, P.-Y., Zhu, Y.-X., Hsieh, C., Lu, J., & Wu, M. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.127540 · Cited by 35
Hicks, N. D., Giffen, S. R., Culviner, P. H., Chao, M. C., Dulberger, C. L., Liu, Q., Stanley, S., Brown, J., Sixsmith, J. D., Wolf, I. D., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009063 · Cited by 35
Inferring multilayer interactome networks shaping phenotypic plasticity and evolution
Yang, D., Jin, Y., He, X., Dong, A., Wang, J., & Wu, R. (2021) · Nature Communications · doi:10.1038/s41467-021-25086-5 · Cited by 34
Liu, X., de Bakker, V., Heggenhougen, M. V., Mårli, M. T., Frøynes, A. H., Salehian, Z., Porcellato, D., Angeles, D. M., Veening, J., & Kjos, M. (2024) · mSystems · doi:10.1128/msystems.01289-23 · Cited by 34
Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011
Hanaki, H., Cui, L., Ikeda-Dantsuji, Y., Nakae, T., Honda, J., Yanagihara, K., Takesue, Y., Matsumoto, T., Sunakawa, K., Kaku, M., et al. (2014) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2014.06.012 · Cited by 34
Ludwig, F., Edwards, B., Lawes, T., & Gould, I. M. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01158-12 · Cited by 34
Pereira, M. R., Rana, M. M., & Practice, T. A. I. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13611 · Cited by 34
Sharma, R., & Hammerschlag, M. R. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0695-4 · Cited by 34
Donkor, E. S., & Kotey, F. C. N. (2020) · Infectious Diseases Research and Treatment · doi:10.1177/1178633720976581 · Cited by 35
A Review on Antistaphylococcal Secondary Metabolites from Basidiomycetes
Vallavan, V., Krishnasamy, G., Zin, N. M., & Latif, M. A. (2020) · Molecules · doi:10.3390/molecules25245848 · Cited by 35
Aros-Calt, S., Muller, B. H., Boudah, S., Ducruix, C., Gervasi, G., Junot, C., & Fenaille, F. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00697 · Cited by 34
Liu, S., Li, Z., Li, C., Liu, S., Lang, Y., Zhang, X., Zhang, B., & Liu, C. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.135877 · Cited by 33
da Costa, T. M., Morgado, P. G. M., Cavalcante, F. S., Damasco, A. P., Nouér, S. A., & dos Santos, K. R. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160506 · Cited by 33
Safety of topical vancomycin powder in neurosurgery
Abdullah, K., Chen, H., & Lucas, T. (2016) · Surgical Neurology International · doi:10.4103/2152-7806.195227 · Cited by 33
Metadata
- Authors
- Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L.
- Affiliations
- The University of Melbourne (AU)
- Monash University (AU)
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2010-01
- Volume
- 23
- Issue
- 1
- Pages
- 99-139
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- PMC
- PMC2806658
- OpenAlex
- W2126915534
- Cited by
- 962
- References
- 406
- Citations by year
- 2026: 42 · 2025: 41 · 2024: 48 · 2023: 58 · 2022: 45 · 2021: 52 · 2020: 49 · 2019: 60 · 2018: 54 · 2017: 51 · 2016: 63 · 2015: 83 · 2014: 69 · 2013: 88 · 2012: 72
- FWCI
- 9.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Microbiology Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin-intermediate Staphylococcus aureus, heterogeneous vancomycin-intermediate Staphylococcus aureus, reduced vancomycin susceptibility, glycopeptide resistance, cell wall thickening, agr gene, vancomycin susceptibility testing, treatment failure, host-pathogen interaction
- MeSH terms
- Anti-Bacterial Agents, Humans, Microbial Sensitivity Tests, Staphylococcal Infections, Staphylococcus aureus, Vancomycin, Treatment Outcome, Vancomycin Resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
